Abstract: Modafinil is a wake-promoting agent approved by the Federal Drug Administration for the treatment of narcolepsy. Preliminary evidence indicates that modafinil may improve fatigue and excessive sleepiness associated with a variety of conditions. The purpose of this study was to investigate the utility of modafinil as an adjunctive treatment of depressed patients. Subjects with a history of major depression with partial response on a stable therapeutic dose of an antidepressant were eligible to participate. All subjects endorsed complaints of significant fatigue and/or excessive sleepiness on clinical assessment. Modafinil was added to their existing regimen at a dose of 100 to 400 mg/d for 4 weeks. Subjects were assessed at 2-week intervals for improvement using the standard depression scales (HDRS, BDI, CGI), fatigue scales (VASF, FSI), and a neuropsychologic battery. Thirty-five subjects were entered and 31 subjects completed the 4-week trial. Significant improvements were seen across all 3 measures of depression (HDRS, BDI, CGIS) and both measures of fatigue (VASF, FSI). On the neurocognitive battery, significant gains in the Stroop Interference Test were seen at 4 weeks, whereas the other cognitive tests showed no change. Modafinil may be a useful and a well-tolerated adjunctive agent to standard antidepressants in the treatment of major depression. (J Clin Psychopharmacol 2004;24:87-90) S timulants have been used for many years as successful adjunctive agents in the treatment of depression.
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S
timulants have been used for many years as successful adjunctive agents in the treatment of depression. [1] [2] [3] [4] [5] [6] [7] Stimulants may be particularly effective in treating the fatigue and sleepiness associated with this disorder. [8] [9] [10] Modafinil is a novel agent that has stimulant-like properties, without the abuse and dependence potential of stimulants. Modafinil has been shown to be an effective wake-promoting agent in the treatment of narcolepsy, for which it is approved by the Federal Drug Administration. [11] [12] [13] It has also proven beneficial in treating the daytime sleepiness associated with obstructive sleep apnea, when used in combination with nasal continuous positive airway pressure therapy. 14, 15 Furthermore, modafinil has been shown to improve fatigue in patients with multiple sclerosis. 16 Modafinil may also affect cognition. A study in mice showed enhanced learning in modafinil-treated mice compared with controls, 17 and a study using modafinil in sleep deprivation found that it was able to counteract the cognitive impairments associated with sleep deprivation states. 18 In addition, preliminary studies of modafinil in the treatment of attention deficit and hyperactivity disorder indicate that the drug may help attention and concentration difficulties in attention deficit and hyperactivity disorder patients. 19, 20 Fatigue, cognitive problems, and hypersomnia or somnolence are common symptoms of depression. Fatigue and somnolence are also common treatment emergent symptoms of antidepressant therapy. Modafinil may be a potentially useful adjuvant in the treatment of major depression. Data on the use of modafinil as an adjunctive agent in the treatment of major depressive disorder are sparse. A retrospective case series of 7 subjects with major depressive disorder or bipolar depression who had a partial response or nonresponse to antidepressant treatment showed clinical benefit with modafinil 100 to 200 mg/d within 1 to 3 weeks, 21 with decreases in Hamilton Depression Rating Scale (HDRS) scores. Schwartz et al 22 recently published a case series of modafinil as an augmentation strategy in the treatment of depression in patients with severe comorbid medical illnesses, many of whom were hospitalized and needed rapid, aggressive intervention. They described 5 cases in which antidepressant augmentation with modafinil led to an average 29% improvement from baseline within approximately a month's time.
In this prospective open-label study, the efficacy of adjunctive modafinil is evaluated in depressed patients who have not been full responders on a standard antidepressant.
disorder by interview were enrolled in the study. Subjects were taken from a population of patients being treated for depression in the adult outpatient psychiatric clinics at Stanford University Hospital. Subjects were included if they had a partial response to 4 weeks of antidepressant medication at a therapeutic dose. Partial response was defined as some improvement on medication, but still with residual symptoms of depression (HDRS score >16), and complaining of hypersomnia, fatigue, daytime somnolence, or impaired daytime alertness. We did not differentiate treatment response from antidepressant-associated asthenia, as we were interested in the effects of modafinil in either case.
We excluded subjects who had a history of sensitivity to modafinil or related drugs, had a history of bipolar illness or mixed bipolar features, met criteria for treatment resistant depression, met criteria for a psychotic disorder, met criteria for substance abuse or dependence in the previous 6 months, presented a significant imminent suicide risk, had a history of liver disease or other major medical illness, were pregnant or planned on becoming pregnant during the study, were not using adequate birth control in the opinion of the investigators, or were concurrently on other stimulants.
Subjects continued to receive their standard antidepressant, and modafinil was added at a starting dose of 100 mg/QD, and titrated upwards as clinically indicated to a maximum dose of 400 mg/QD. Subjects were assessed at 2-week intervals for improvement in their overall depression using the Hamilton Depression Rating Scale (24 item-HDRS), Beck Depression Inventory (BDI), and Clinical Global Impression Scale (CGIS). Subjects rated their alertness, energy level, and overall sense of well-being with the Visual Analog Scale of Fatigue (VASF) and the Fatigue Scale Inventory (FSI), also administered at 2-week intervals. At 4 weeks, a neurocognitive battery was administered, the Stroop Interference Test, the WAIS-III Letter Number Sequencing Test, the WAIS-III Digit Span Forward and Backward Test, the WAIS-III Letter Number Sequencing Test, and Trailmaking A and B.
Statistical analysis was performed using SPSS on a Dell computer. Repeated measures ANOVAs were conducted, with P = 0.05 corrected for family-wise error with a stepwise Bonferroni procedure. Total HDRS, BDI, CGIS, VASF, and FSI scores; items 8, 9, and 13 from the HDRS; and items 15 and 17 from the BDI were dependent variables in those ANOVAs. (No other individual items from the HDRS or BDI were analyzed.) Post hoc comparisons were performed in ANOVAs that showed significance. Again, P was set at 0.05 corrected for family-wise error with a stepwise Bonferroni procedure.
Due to the attrition of 4 subjects, an ITT analysis was conducted which showed no significant differences (at P = 0.05) between completers and noncompleters on the variables of age, gender, and baseline depression scores.
All subjects gave written informed consent prior to their participation in the study. This study was carried out in accordance with Declaration of Helsinki guidelines for ethical standards in human research, and was reviewed and approved by Stanford University Internal Review Board on Research Using Human Subjects.
RESULTS
Of the 35 subjects enrolled in the study, 31 completed the study. The 4 subjects who did not complete the study did not significantly differ from those who remained for age (X completers = 47; X noncompleters = 51), gender (M/F completers = 13:18; M/F noncompleters = 2:2), or baseline depression scores (HDRS: X completers = 21; X noncompleters = 23). Mean age of completers was 48 (range: 26 -72), with 18 women and 13 men. Twenty-seven of the subjects were on only 1 antidepressant and 4 were on 2. The most commonly prescribed antidepressant was venlafaxine (10 subjects), followed by citalopram (8), sertraline (5) and fluoxetine (5), paroxetine (4), and desipramine (1). Secondary antidepressants included mirtazapine (3) and trazodone (3). Mean baseline HDRS score was 21.35 ± 5.97. Mean baseline BDI score was 20.55 ± 9.48. Mean baseline CGIS score was 3.81 ± .91. The average dose of modafinil at week 4 was 275.81 ± 84.53 mg (200 -400 mg).
Hamilton Depression Rating Scale (HDRS) scores at baseline, 2 weeks, and 4 weeks were analyzed using a repeated measures ANOVA, which showed significant differences ( f = 22.14, P < 0.001), (Fig. 1) . Post hoc tests revealed that the decrease from baseline to 2 weeks was significant (t = 4.012, P < 0.001), whereas that between 2 and 4 weeks was not (t = .78, P = 0.441). In looking at individual items on the HDRS which specifically addressed psychomotor retardation (no. 8), psychomotor agitation (no. 9), and loss of energy and fatigability (no. 13), repeated measures ANOVAs revealed no significant changes in psychomotor retardation ( f = 1.37, P = 0.26) or agitation ( f = 0.229, P = 0.796). By contrast, there was a significant decrement in energy and fatigability (item no. 13 on the HDRS) ( f = 21.22, P < 0.001). Again, post hoc tests revealed that this decrement was mostly attributable to changes occurring in the first 2 weeks of the study (t = 5.78, P < 0.001).
Like the HDRS, Beck Depression Inventory (BDI) scores at baseline, 2 weeks, and 4 weeks were analyzed using a repeated measures ANOVA, and also showed significant differences ( f = 20.51, P < 0.001), (Fig. 2) . Again, post hoc tests showed the decrease from baseline to 2 weeks was significant (t = 5.00, P < 0.001), whereas that between 2 and 4 weeks was not (t = .40, P = 0.69). Individual items on the BDI, specifically addressing effort to perform a task (no. 15) and getting tired more easily (no. 17), were analyzed using repeated measures ANOVAs. Significant decreases in effort (ANOVA; F = 12.40, P < 0.001) and improvements in tiredness (ANOVA; F = 22.63, P < 0.001) were both evident, and again, the improvements occurred between baseline and 2 weeks.
Mean Visual Analog Scale of Fatigue (VASF) scores at baseline, 2 weeks, and 4 weeks were also significantly different ( f = 35.56, P < 0.0001), with most the change occurring within the first 2 weeks of being on Modafinil (t = 6.55, P < 0.001), (Fig. 3) . Mean Fatigue Scale Inventory (FSI) scores at baseline, 2 weeks, and 4 weeks were different ( f = 32.13, P < 0.001), again with significant improvements occurring only between baseline and week 2 (t = 6.32, P < 0.0001), (Fig. 4) .
Mean Clinical Global Impression Scale (CGIS) scores at baseline, 2 weeks, and 4 weeks were significantly different ( f = 18.20, P < 0.001); again, the improvement was attributable to changes within the first 2 weeks (t = 5.67, P < 0.0001).
On the neurocognitive battery, the Stroop Interference Test was the only test to show a significant difference between baseline and week 4 (t = À3.20, P < 0.004). No other neurocognitive test showed a significant change from baseline: WAIS-III Letter Number Sequencing Test, the WAIS-III Digit Span Forward and Backward Test, the WAIS-III Letter Number Sequencing Test, or the Trailmaking A and B.
A total of 13 of the subjects (41.9% of the sample) had a 50% reduction or better on the HDRS and BDI.
DISCUSSION
In this 4-week, prospective, open-label study in subjects with major depression and partial response to antidepressant therapy, adjunctive treatment with modafinil rapidly improved fatigue and overall depressive symptoms. Improvement was seen as early as 2 weeks and persisted at 4 weeks. Treatment was well tolerated and did not appear to adversely affect neurocognitive function. Modafinil may even enhance those aspects of cognition related to executive function.
Our findings are consistent with the previous study of modafinil antidepressant augmentation, which found improvements in fatigue and daytime sleepiness with the addition of modafinil. Our results, like those of Menza et al, 21 showed improvements in overall depression levels above and beyond improvements in fatigue. The antidepressant effects of modafinil may be related to possible enhancement of 5HT neurotransmission. Furthermore, the study assessed the effects of modafinil on neurocognitive function, which, as far as we know, has not been previously examined in the context of major depression. Modafinil improved scores from baseline to 4 weeks on a test of executive function (Stroop Interference Test). These findings suggest that modafinil may be particularly effective in combating the cognitive impairments often seen in major depression.. Future studies with modafinil may want to target populations of depressed subjects who complain of cognitive difficulty as a symptom of their depression, just as ours and previous studies have targeted residual fatigue.
Of note is the finding of the rapid onset of modafinil efficacy, which occurred by the 2-week mark and persisted at 4 weeks. This finding may have implications in clinical practice, as most of our antidepressant strategies take several weeks to months to have their effect. There are numerous clinical situations in which this type of time delay may greatly increase morbidity and mortality.
The analysis of individual items on the HDRS and BDI revealed that items specifically addressing fatigue and effort were significantly improved over the course of the study, consistent with the improvements seen on the scales addressing fatigue, the Mean Visual Analog Scale of Fatigue (VASF) and the Mean Fatigue Scale Inventory (FSI). However, psychomotor retardation (HDRS) was not significantly improved over the course of the study. The discrepancy may be related to that this is one of the few items on the HDRS, which is not subjectively rated by the subject, but rather, observed and rated by the interviewer. In addition, it is likely that psychomotor retardation is distinct from fatigue.
Our findings are limited by the small sample size and open-label design, as well as potential carry-over effects from existing antidepressants. Another potential limitation of this study is the lack of assessment of depressive symptoms at baseline antidepressant treatment. Double-blind placebocontrolled trials are required to establish modafinil's efficacy as a treatment strategy for major depression. In the meantime, this study provides promising preliminary evidence for a role for modafinil as an augmentation strategy, particularly in cases of residual fatigue, need for rapid efficacy, and possibly cognitive impairment.
